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Between 9/01 and 8/03 13 patients with relapsed/refractory lym-
phoid malignancies have undergone NST. The median age at
transplantation was 52 years (range 21-63). The median number of
prior therapies was 5 (range 1-7). Diseases transplanted repre-
sented a broad variety of lymphoid malignancies including
Hodgkin’s disease (n 3) and non-Hodgkin’s lymphoma (n 10).
The conditioning regimen consisted of Pentostatin 4 mg/m2/day
IV on days -21, -20, and -19, followed by low dose total body
irradiation on day –1. Graft-versus-host disease (GVHD) prophy-
laxis consisted of cyclosporine/mycophenolate mofetil. Stem cell
transplantation was from matched related (n  5) or matched
unrelated (n  8) donors. All toxicities were minimal. At day 28
the median values for donor chimerism were 90% (range 55%-
100%) for CD3 cells and 95% (range 50%-100%) for WBC. At
day 70 the respective median values were 95% (range 50%-
100%) and 100% (range 80%-100%) respectively. Sustained en-
graftment has been observed in all cases to date and no patients
have required donor leukocytes. Acute GVHD has been seen in
6/13 patients, and chronic GVHD in 6/8 evaluable patients. Treat-
ment related mortality is 15% (one death from intracranial hem-
orrhage, one death from chronic GVHD). With a median fol-
low-up for surviving patients of 11.2 months, the event-free
survival and overall survival are presently projected at 73%. Of six
patients who underwent autologous stem cell transplantation as
their immediate prior therapy (excluding salvage therapy prior to
NST), ﬁve have had remission durations which have exceeded their
prior remission duration with autologous transplantation (P 0.07
by logrank). An additional patient with Waldenstrom’s macroglob-
ulinemia had evidence of minimal residual disease (persistent mar-
row disease and an elevated IgM) for six months post transplant,
and with no further therapy at one year post transplant has a
normal marrow and IgM levels. The use of Pentostatin/TBI as a
preparative regimen for NST in patients with refractory/relapsed
lymphoid malignancies is associated with minimal toxicity, sus-
tained engraftment, and an acceptable treatment related mortality
given the patient population. The observation that a number of
patients have had remission inversions (compared with immedi-
ately prior high-dose chemotherapy/autologous stem cell trans-
plantation) and the occurrence of a late remission in the absence of
other therapy offers indirect evidence of a graft-versus-lymphoma
effect.
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Mantle cell lymphoma (MCL) is a B-cell lymphoma with tumor
cells that are typically CD5 and CD23- and overexpress cyclin
D1. The response rate and overall survival in patients with MCL
are signiﬁcantly lower than other types of lymphoma. No chemo-
therapeutic regimen has been proven to be consistently curative for
MCL. The role of hematopoietic stem cell transplantation
(HSCT) in the treatment of MCL is unclear. Also it is not known
which type of transplantation is more effective. Hence we studied
the clinical course of the disease in patients who received autolo-
gous or allogeneic HSCT for MCL to determine if the type of
transplant had an effect on the clinical outcome. Ninety seven
patients who received HSCT for MCL were studied, including 80
patients who received an autologous HSCT and 17 patients who
received an allogeneic HSCT from a matched sibling donor. None
of the allogeneic transplants employed a reduced intensity prepar-
ative regimen. Primary end points were response at day 100,
mortality at day 100, relapse rate (RR), event free survival (EFS)
and overall survival (OS). Patients who received an autologous
HSCT were older (median age: 56 yrs vs. 47 yrs) (p  0.01) and
were less likely to receive conditioning with total body irradiation
(9% vs. 94%) (p  0.0001). There was no signiﬁcant difference in
the complete response rate at day 100 between patients receiving
autologous and allogeneic HSCT (73% vs. 62%). Mortality at day
100 was higher among recipients of allogeneic HSCT (19%) as
compared to autologous HSCT (0%) (p  0.01). The estimated
5-yr RR was 21% among patients receiving an allogeneic HSCT
compared to 56% for those receiving an autologous HSCT (p 
0.11). The estimated 5-yr EFS was 44% for allogeneic HSCT and
39% for autologous HSCT (p 0.85). The estimated 5-yr OS was
49% for allogeneic HSCT and 47% for autologous HSCT (p 
0.51). Ten patients (8 autologous HSCT, 2 allogeneic HSCT)
received HyperCVAD (hyperfractionated cyclophosphamide, vin-
cristine, doxorubicin and dexamethasone) prior to transplant and
there have not been any relapses or deaths amongst these patients
at a median follow-up of 16 months. In conclusion, allogeneic
HSCT patients tended to have a lower relapse rate, although this
difference was not statistically signiﬁcant. However the OS and
EFS were similar in both groups. Both types of transplants can lead
to long-term disease-free survival in approximately 40% patients
with MCL especially after chemotherapy with HyperCVAD.
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Previous studies in multiple myeloma have demonstrated a sig-
niﬁcant association between survival and lymphocyte recovery fol-
lowing autologous transplantation (Porrata et al., Blood 2001). Fur-
thermore, in a murine model of myeloma, adoptive transfer of
activated T cells following bone marrow transplantation has dem-
onstrated a marked anti-tumor effect in vivo (Hou Fowler, BBMT
2003). We have initiated a clinical trial in patients with multiple
myeloma to evaluate the activity of T cells activated and expanded
ex vivo with the Xcellerate™ Process, which uses anti-CD3 and
anti-CD28 antibodies covalently linked to magnetic beads
(Xcyte™ Dynabeads®). Following induction therapy, patients un-
dergo a leukapheresis to collect peripheral blood mononuclear cells
for the Xcellerate Process. Patients then undergo stem cell mobi-
lization and collection, followed by high dose chemotherapy with
melphalan (200 mg/m2). Three days following peripheral blood
stem cell infusion, patients receive an infusion of 5-10  1010
autologous Xcellerated T Cells. Thirty-one of the planned 35
patients have been treated to date. T cells have been successfully
activated and expanded in all patients. In the ﬁrst 18 patients, T
cells expanded 166  44 fold (mean  SD), with the ﬁnal product
being 99.0  0.1% CD3. A bioreactor process was subse-
quently instituted, and T Cells expanded 253  86 fold, with ﬁnal
product 98.0 3.2% CD3 (n 10). Xcellerated T Cell infusions
have been well-tolerated, with no Grade 3 or 4 acute infusional
toxicities. Lymphocyte recovery has been rapid, with counts reach-
ing 500/mm3 generally within 1-2 days following T cell infusion
(Day 4-5 post transplant). Historically, lymphocyte recovery to
500/mm3 usually does not occur for 3 or more weeks post-
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